US stocks are landing at Stockopedia Find out more
Registered:
4/06/09
Seen:
Tue 11:12am
Followers:
1026

Documents
6710

Occupation: Research House

Interests: Stocks

Twitter: Edison_Inv_Res

About Me:

Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants.

Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries.

Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).



Investment Research

Run by a team of highly experienced professionals, our aim is to provide the research of choice for companies, investment banks and institutional investors. We provide independent reports, forecasts and valuations on each company we cover. We help clients gain access to investors, and facilitate feedback from the investment community on companies, their management and strategies. Our research strives to be objective, insightful, financially rigorous, readable and timely.

Web Address: http://www.edisongroup.com

Address: 280 High Holborn
London
WC1V 7EE

Tel: Tel: +44 (0)20 3077 5700

Find out More »


Edison Investment Research's Latest Blogs

TiGenix is developing clinical studies in rheumatoid arthritis and sepsis for Cx611, its expanded adipose stem cell (eASC) intravenous therapy. The first stage planned is a pilot volunteer sepsis study starting in early 2015 with data possible in Q315. The Phase II RA study from Q315 will focus on achieving minimal disease activity in patients who fail to respond to initial treatment with standard agents.…

MagForce’s strategy to increase uptake of its NanoTherm therapy is on track and progress has been made in both Europe and the US in line with expectations. In Europe the installed base of NanoActivators has increased and the first patient was enrolled into the post-marketing glioblastoma (GBM) study. In the US, a positive pre-submission meeting was held with the FDA, confirming that NanoTherm will be…

In a recent meeting with the FDA, Epigenomics obtained clarity on how to design patient compliance trials, which should enable a launch of Epi proColon by mid-year 2015. Plans to secure more funding before a US launch are likely with the share price at an attractive entry level.

Utilico Emerging Markets Limited (UEM) is a closed-end investment company investing in utilities, infrastructure and related companies in emerging markets. Its specific sector focus differentiates it from other emerging market funds, as does its dividend yield of over 3%, reflecting its focus on cash-generative businesses. NAV total return performance has exceeded peer group averages over one, three and five years and it has the lowest…

Evonik’s consolidation of its partnership with Borussia Dortmund is a strong endorsement of management’s development of the BVB brand. Long-term extension of its leading sponsorship agreement enhances Dortmund’s revenue security while c €26m proceeds from Evonik’s new 9% stake will address a current spike in net player spend. The prospect of further partnerships, secured by capital increases, is welcome in terms of cash and the…



Edison Investment Research's Top Awards 25



Edison Investment Research Followers

Edison Investment Research has 1026 followers including:


and 1018 more.